|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
111,521,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vaxxinity is a biotechnology company. Co.'s pipeline consists of five chronic disease product candidates including UB-311, which targets toxic forms of aggregated Ab in the brain to fight Alzheimer's Disease; UB-312, which targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's Disease and other synucleinopathies; an anti-tau product candidate that has the potential to address various neurodegenerative conditions; UB-313, which targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9, which targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
362,934 |
Total Buy Value |
$0 |
$0 |
$0 |
$776,028 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
9 |
Total Shares Sold |
0 |
0 |
96,936 |
1,191,214 |
Total Sell Value |
$0 |
$0 |
$168,588 |
$3,463,338 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
6 |
20 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Chui James |
Director |
|
2021-12-31 |
4 |
B |
$5.48 |
$32,880 |
D/D |
6,000 |
14,000 |
2.39 |
- |
|
Chui James |
Director |
|
2021-12-10 |
4 |
B |
$7.89 |
$63,120 |
D/D |
8,000 |
8,000 |
2.39 |
- |
|
Diamandis Peter |
Director |
|
2021-11-18 |
4/A |
S |
$13.00 |
$3,224 |
D/D |
(248) |
90,499 |
|
- |
|
Diamandis Peter |
Director |
|
2021-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
76,923 |
76,923 |
|
- |
|
Diamandis Peter |
Director |
|
2021-11-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(76,923) |
0 |
|
- |
|
Blatt Gregory R |
Director |
|
2021-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
76,923 |
76,923 |
|
- |
|
Blatt Gregory R |
Director |
|
2021-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(76,923) |
0 |
|
- |
|
Diamandis Peter |
Director |
|
2021-11-15 |
4/A |
A |
$0.00 |
$0 |
I/I |
13,824 |
13,824 |
|
- |
|
Diamandis Peter |
Director |
|
2021-11-15 |
4/A |
A |
$0.00 |
$0 |
D/D |
13,824 |
13,824 |
|
- |
|
Palm Ulo |
Chief Medical Officer |
|
2021-11-15 |
4 |
B |
$13.00 |
$5,850 |
I/I |
450 |
450 |
1.99 |
- |
|
Blatt Gregory R |
Director |
|
2021-11-15 |
4 |
B |
$0.00 |
$0 |
I/I |
76,923 |
76,923 |
2.02 |
- |
|
Blatt Gregory R |
Director |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
I/I |
836,737 |
160,668 |
|
- |
|
Diamandis Peter |
Director |
|
2021-11-15 |
4 |
B |
$0.00 |
$0 |
I/I |
76,923 |
76,923 |
2.02 |
- |
|
Diamandis Peter |
Director |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
I/I |
271,655 |
271,655 |
|
- |
|
United Biomedical Inc |
10% Owner |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
I/I |
4,212,495 |
4,212,495 |
|
- |
|
United Biomedical Inc |
10% Owner |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
247,050 |
51,585,416 |
|
- |
|
Sloss Dakin |
10% Owner |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,738,192 |
9,738,192 |
|
- |
|
Sloss Dakin |
10% Owner |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
I/I |
8,289,122 |
3,615,038 |
|
- |
|
Hu Mei Mei |
See Remarks |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
I/I |
4,731,200 |
4,212,495 |
|
- |
|
Reese Lou |
Executive Chairman |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
I/I |
4,731,200 |
4,212,495 |
|
- |
|
Hu Mei Mei |
See Remarks |
|
2021-11-12 |
4 |
B |
$13.82 |
$241,920 |
I/I |
17,500 |
17,500 |
2.64 |
- |
|
Reese Lou |
Executive Chairman |
|
2021-11-12 |
4 |
B |
$13.82 |
$241,920 |
D/D |
17,500 |
17,500 |
2.81 |
- |
|
Diamandis Peter |
Director |
|
2021-11-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,099,915 |
|
- |
|
Hu Mei Mei |
See RemarksOfficer |
|
2021-11-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,955,512 |
|
- |
|
Hu Mei Mei |
See RemarksOfficer |
|
2021-11-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,518,961 |
|
- |
|
81 Records found
|
|
Page 3 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|